ATHE ALTERITY THERAPEUTICS LIMITED
Price Chart
Executive Summary
Alterity Therapeutics highlighted positive Phase 2 clinical data for its lead candidate ATH434 in Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disease with no approved therapies. The company is preparing to initiate a Phase 3 pivotal trial, supported by clinically and statistically significant results on functional outcomes, biomarker evidence of target engagement, and a favorable safety profile.
Actionable Insight
Traders should monitor for the initiation of the Phase 3 trial announcement and any upcoming regulatory interactions or trial design details, which could serve as near-term catalysts. Given the lack of approved MSA therapies and strong Phase 2 data, successful Phase 3 outcomes could position ATH434 as a first-in-class therapy with significant commercial potential.
Key Facts
- ATH434 demonstrated clinically and statistically significant improvement on the mUMSARS Part I scale versus placebo in a Phase 2 trial.
- The Phase 2 trial was randomized, double-blind, placebo-controlled, and included 77 patients treated for 12 months.
- Both 50 mg and 75 mg doses of ATH434 reduced brain iron accumulation and showed trends in preserving brain volume.
- ATH434 was well tolerated with no serious adverse events attributed to the drug.
- FDA Fast Track and Orphan Drug designations have been granted for ATH434 in MSA.
- Alterity is preparing to initiate a Phase 3 pivotal trial in MSA.
Financial Impact
No direct financial figures disclosed, but advancement to Phase 3 represents a major value inflection point for a clinical-stage biotech with a $53M market cap.
Risk Factors
- Phase 3 trial may not replicate Phase 2 results despite promising data.
- High risk of future dilution given the company's clinical-stage status and likely need for additional funding.
- Small market size due to MSA's rarity may limit peak revenue potential unless expanded to other Parkinsonian disorders.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247257 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
Press Release
| $3.92 awaiting T+5 | awaiting T+5 | — | $3.92 (+0.00%) |
|
May 11, 2026
29d ago
|
Press Release
| $4.80 $4.34 | ▼ −9.58% | ▼ −9.50% | $3.92 (−18.33%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $4.54 $4.67 | ▲ +2.86% | ▲ +1.14% | $3.92 (−13.66%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.62 $4.52 | ▼ −2.16% | ▼ −2.56% | $3.92 (−15.15%) |
|
Apr 22, 2026
6w ago
|
Press Release
| $4.54 $4.57 | ▲ +0.66% | ▲ +0.61% | $3.92 (−13.66%) |
|
Mar 26, 2026
10w ago
|
6-K
| $3.16 $3.56 | ▲ +12.66% | ▲ +11.02% | $3.92 (+24.05%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $3.45 $3.55 | ▲ +2.90% | ▲ +4.11% | $3.92 (+13.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access